|Group identity and social preferences|
Y Chen, SX Li
American Economic Review 99 (1), 431-57, 2009
|Social comparisons and contributions to online communities: A field experiment on movielens|
Y Chen, FM Harper, J Konstan, SX Li
American Economic Review 100 (4), 1358-98, 2010
|Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial|
DW Kim, R Mehra, DSW Tan, E Felip, LQM Chow, DR Camidge, ...
The lancet oncology 17 (4), 452-463, 2016
|Social identity and inequality: The impact of China's hukou system|
F Afridi, SX Li, Y Ren
Journal of Public Economics 123, 17-29, 2015
|Which hat to wear? Impact of natural identities on coordination and cooperation|
Y Chen, SX Li, TX Liu, M Shih
Games and Economic Behavior 84, 58-86, 2014
|Social comparisons to motivate contributions to an online community|
FM Harper, SX Li, Y Chen, JA Konstan
International Conference on persuasive technology, 148-159, 2007
|Giving to government: Voluntary taxation in the lab|
SX Li, CC Eckel, PJ Grossman, TL Brown
Journal of Public Economics 95 (9-10), 1190-1201, 2011
|Social distance in a virtual world experiment|
M Fiedler, E Haruvy, SX Li
Games and Economic Behavior 72 (2), 400-426, 2011
|A phase I study of PF-04449913, an oral hedgehog inhibitor, in patients with advanced solid tumors|
AJ Wagner, WA Messersmith, MN Shaik, S Li, X Zheng, KR McLachlan, ...
Clinical Cancer Research 21 (5), 1044-1051, 2015
|Social identities, ethnic diversity, and tax morale|
S Xin Li
Public Finance Review 38 (2), 146-177, 2010
|Group identity in markets|
SX Li, K Dogan, E Haruvy
International Journal of Industrial Organization 29 (1), 104-115, 2011
|ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer|
AT Shaw, BJ Solomon, B Besse, TM Bauer, CC Lin, RA Soo, GJ Riely, ...
Journal of Clinical Oncology 37 (16), 1370-1379, 2019
|Profits, layoffs, and priorities|
DG Arce, SX Li
Journal of Business Ethics 101 (1), 49-60, 2011
|Phase II open-label study of sunitinib in patients with advanced breast cancer|
DA Yardley, EC Dees, SD Myers, S Li, P Healey, Z Wang, MJ Brickman, ...
Breast cancer research and treatment 136 (3), 759-767, 2012
|Breast cancer, early stage|
TSK Mok, L Paz-Ares, YL Wu, S Novello, E Juhasz, O Aren, Y Sun, ...
Annals of Oncology 23 (suppl_9), ixe1-ixe30, 2012
|Abstract CT044: efficacy of lorlatinib in patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC) and ALK kinase domain mutations|
AT Shaw, JF Martini, B Besse, TM Bauer, CC Lin, RA Soo, GJ Riely, ...
Cancer Research 78 (13 Supplement), CT044-CT044, 2018
|OA12. 02 updated antitumor activity of crizotinib in patients with MET exon 14-altered advanced non-small cell lung cancer|
A Drilon, J Clark, J Weiss, S Ou, DR Camidge, B Solomon, G Otterson, ...
Journal of Thoracic Oncology 13 (10), S348, 2018
|Immune biomarkers predictive for disease-free survival with adjuvant sunitinib in high-risk locoregional renal cell carcinoma: from randomized phase III S-TRAC study|
DJ George, JF Martini, M Staehler, RJ Motzer, A Magheli, B Escudier, ...
Clinical Cancer Research 24 (7), 1554-1561, 2018
|First report of safety, PK, and preliminary antitumor activity of the oral EGFR/HER2 exon 20 inhibitor TAK-788 (AP32788) in non–small cell lung cancer (NSCLC).|
RC Doebele, GJ Riely, AI Spira, L Horn, Z Piotrowska, DB Costa, JW Neal, ...
Journal of Clinical Oncology 36 (15_suppl), 9015-9015, 2018
|Common identity and the voluntary provision of public goods: An experimental investigation|
SX Li, ACM de Oliveira, C Eckel
Journal of Economic Behavior & Organization 142, 32-46, 2017